AXPAXLI (axitinib intravitreal implant)

Neovascular age-related macular degeneration

Also known as OTX-TKI

Manufacturer: Ocular Therapeutix
Regulatory submission: NDA planned for the fourth quarter of 2026
Launch: Anticipated in 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of axitinib intravitreal implant on other drugs

2 evidence topics · 2 sources

Clinical drug interaction studies with the intravitreal implant

No evidence found.

Class context: oral axitinib (INLYTA) effects on CYP enzymes and transporters

“In vitro studies demonstrated that axitinib has the potential to inhibit CYP1A2 and CYP2C8. However, co-administration of axitinib with paclitaxel, a CYP2C8 substrate, did not increase plasma concentrations of paclitaxel in patients.” (opens the source at this quote in a new tab)
“Axitinib is an inhibitor of the efflux transporter P-glycoprotein (P-gp) in vitro. However, INLYTA is not expected to inhibit P-gp at therapeutic plasma concentrations.” (opens the source at this quote in a new tab)

Preclinical systemic exposure with repeat intravitreal dosing

“Plasma samples revealed minimal to no systemic axitinib exposure over the study duration” (opens the source at this quote in a new tab)